CDMO Recipharm has announced an extension of its existing partnership with spray nozzle developer and manufacturer Medspray to include development of soft mist nasal delivery devices. In February 2021, Recipharm and Medspray announced the launch of their joint venture Resyca to develop soft mist inhalation products using Medspray nozzle technology.
The new agreement gives Resyca exclusive rights to the use of that nozzle technology for nasal and combination products, and the companies expect that the new development projects will focus on nasal delivery of biologics, Recipharm said.
Medspray CEO Han van Egmond commented, “Extending this agreement involves combining our cutting-edge nasal technology with Resyca’s product development capabilities. This collaboration with Resyca will enable us to bring innovative solutions to the market that will redefine the landscape of nasal drug delivery.”
Resyca CEO Remko Beimers added, “We are thrilled to enter into this extended strategic partnership with Medspray. This move aligns perfectly with our mission to pioneer advancements in aerosol drug delivery systems. The exclusive license from Medspray will significantly strengthen our position in the market, allowing us to bring innovative and effective soft mist nasal delivery devices to patients worldwide together with our pharma customers.”
Recipharm President, Advanced Delivery Systems, Chris Hirst said, “We are proud to be associated with Medspray and Resyca in this landmark licensing agreement. As a CDMO committed to driving innovation, we look forward to supporting both companies in bringing their pioneering soft mist nasal delivery devices to the market to improve patient experience and expand what is possible via the nasal delivery route.”
Read the Recipharm press release.
